Product: Metronidazole Vaginal Tablets
Brand: Metro V-250
Composition: Metronidazole BP 250 mg per uncoated vaginal tablet
Route: Intravaginal only
Usage: Selected vaginal infections, subject to approved labeling
Category: Antibiotic Drugs
Therapeutic category: Nitroimidazole antibacterial / antiprotozoal
SKU: Metronidazole Vaginal Tablets
Categories: Contract Manufacturer, Formulations Exporter India, Manufacturing Pharmaceutical Company India, Pharmaceutical Exporter India, Pharmaceutical Formulations India, Tablets Manufacturer, WHO GMP Certified Formulations
Metronidazole Vaginal Tablets is listed in our pharmaceutical product portfolio for business-to-business enquiries. Product-specific formulation details, available strengths, dosage form, pack configuration and supply terms should be confirmed against the current product specification before ordering.
For distributor, wholesaler, hospital procurement and export enquiries, please request the applicable product specifications, batch documentation, shelf-life information, packaging options and regulatory documents. Availability and documentation depend on the product and destination market.
Manufacturer: Healthy Life Pharma Pvt. Ltd. (WHO-GMP status subject to verification)
Exporter: Healthy Inc (export credentials subject to verification)
Metro V-250 is identified in the supplied product composition as a metronidazole BP 250 mg uncoated vaginal tablet, intended for intravaginal use. Metronidazole is a nitroimidazole antibacterial and antiprotozoal agent. Vaginal products may be prescribed for selected vaginal infections according to the formulation's approved local labeling.
Healthy Life Pharma Pvt. Ltd. is listed as manufacturer and Healthy Inc as exporter in the supplied information. Contract-manufacturing capabilities, WHO-GMP certification and export credentials require documentary verification.
Strength clarification: The heading in the supplied marketing description says 500 mg, but the only explicitly identified vaginal tablet composition is Metro V-250, 250 mg. The 200 mg, 400 mg and 500 mg products elsewhere in the supplied list are oral tablets, not confirmed vaginal strengths.
| Product name | Metronidazole Vaginal Tablets |
|---|---|
| Brand | Metro V-250 |
| Composition | Each uncoated vaginal tablet contains Metronidazole BP 250 mg |
| Confirmed strength | 250 mg |
| Route | Intravaginal only — not for swallowing |
| Dosage form | Uncoated vaginal tablet |
| Pharmacopoeial reference | BP stated for active ingredient; finished-product compliance requires verification |
| CAS number | 443-48-1 (metronidazole) |
| Therapeutic class | Nitroimidazole antibacterial / antiprotozoal |
| Category | Antibiotic Drugs |
| SKU | Metronidazole Vaginal Tablets |
| Packaging / shelf life | To be verified from approved product specifications and stability studies |
Vaginal tablet development requires route-appropriate tablet geometry, surface characteristics, disintegration performance in limited vaginal fluid, excipient compatibility and microbiological quality. Applicator inclusion and blister materials depend on the registered presentation.
The supplied description refers to shaped tooling, hydrophilic disintegrants and pH compatibility; these are proposed technical features and should not be represented as verified manufacturing methods without supporting formulation records.
Applicable release and stability testing may include identity, assay, content uniformity, disintegration or dissolution as required, related substances, microbial quality, packaging integrity and stability. Limits and test methods must be those in the approved specification and applicable pharmacopoeia.
Claims of specific dissolution times, guaranteed potency, 36-month shelf life, WHO-GMP status and regulatory certifications require current documentary support.
Metronidazole acts against susceptible anaerobic microorganisms and certain protozoa after intracellular reduction of its nitro group, which leads to damage of microbial DNA.
Bacterial vaginosis: Some locally approved intravaginal metronidazole formulations are used for BV. Efficacy and dosing must be established for this specific 250 mg vaginal tablet, rather than inferred from vaginal gel or oral products.
Trichomoniasis: Intravaginal metronidazole alone is not an adequate substitute for recommended oral treatment of trichomoniasis; systemic treatment and partner management are generally required. Do not advertise this tablet as a stand-alone treatment for trichomoniasis without an approved indication.
Claims relating to skin infections, rosacea and mouth infections refer to different formulations and should not be used as indications for this vaginal product.
International registration may require country-specific CTD/ACTD documentation, approved product artwork, stability data, manufacturing authorization, certificates of analysis and any required import/export permissions. Availability of COPP, FSC, GMP certificates, dossiers and specific shipping terms must be confirmed with the supplier.
Q: Which vaginal strength is confirmed?
A: The supplied Metro V-250 label identifies metronidazole BP 250 mg per uncoated vaginal tablet. A 500 mg vaginal tablet has not been confirmed.
Q: Can Metro V-250 be taken orally?
A: No. It is described as a vaginal tablet and must not be swallowed.
Q: Is it appropriate for trichomoniasis?
A: Intravaginal metronidazole is not recommended as the sole treatment for trichomoniasis. Consult a clinician for recommended systemic treatment and partner management.
Q: Should alcohol be avoided?
A: Follow the approved product leaflet and clinician advice. Alcohol warnings vary across product labeling and guidance; do not assume that a vaginal formulation has zero systemic absorption.
Q: Can it be used during menstruation or pregnancy?
A: Follow the specific approved leaflet and a clinician's advice. Do not stop or alter treatment solely on general website guidance.
Route: Intravaginal use only. The correct number of tablets, timing, duration, and whether an applicator is required must come from the approved Metro V-250 package insert or a qualified prescriber. A generic “one tablet nightly for 5–7 days” schedule cannot be validated from the provided composition alone.
Wash hands before and after use. Follow the supplied device instructions, if an applicator is provided. Do not use oral metronidazole tablets vaginally or substitute strengths without professional guidance.
Possible adverse effects include vaginal irritation, burning, itching, discharge and, depending on systemic absorption, nausea, metallic taste or other effects. Seek medical advice for worsening symptoms, severe irritation, allergic reactions or persistent infection.
Tell a clinician about pregnancy, breastfeeding, liver disease, neurological disorders and other medicines, including warfarin and disulfiram. A confirmed diagnosis matters because yeast infections, BV and trichomoniasis require different treatment approaches. Sexual-partner treatment may be needed for sexually transmitted infections.
Store in the original protective packaging and follow the temperature, moisture and light conditions on the approved product label. The supplied recommendation of below 25°C and the proposed 36-month shelf life require confirmation from stability data. Keep out of reach of children.